Published Date: 22 Jul 2026
Waiting for prior authorization of drugs affects a small portion of patients with age-related macular degeneration, resulting in vision loss.
Read Full NewsFaricimab may stabilize vision, reduce retinal fluid and thickness, and cut treatment burden in difficult-to-treat cases of wet age-related macular degeneration.
The U.S. Food and Drug Administration on Monday defended publicizing a lettuce sample later found to be a false positive for cyclospora, saying the reversal does not...
Cyclospora, the parasite behind thousands of suspected U.S. cases of a foodborne illness, has a long incubation period, and samples cannot be cultured in labs, making it...
Sri Lanka's public health services and hospitals are battling the worst outbreak of mosquito-borne dengue in nearly a decade, and turning to the island nation's armed...
Older adults with lower gastrointestinal bleeding present with more severe disease and substantially higher 30-day mortality—yet most deaths stem not from bleeding itself, but from decompensation of underlying chronic conditions.
A prospective multicenter study validates three cerebrospinal fluid biomarkers that may aid diagnosis of suspected primary CNS lymphoma.
The VITAL system collects near real-time hospital data with the aim of optimizing healthcare delivery, research, and innovation while protecting privacy.
1.
Results for Prostate Cancer Are Associated With PSA Nadir 6 Months After Primary RT.
2.
Alecensa (alectinib) Offers Hope for Certain Patients With ALK Positive NSCLC
3.
In Biochemically Recurrent Nonmetastatic Prostate Cancer, Apalutamide Presents Its Argument.
4.
Cancer screening rates down among American adults
5.
For patients with clear cell renal cell carcinoma, a new PET agent allows for same-day imaging.
1.
Modern Oncology Education in the Era of Targeted Therapies
2.
The Miracle of Tenecteplase: How This Drug Is Saving Lives
3.
Essential Perspectives in Hematology and Patient Outcomes
4.
CENP-H in Cancer: A Key Player in Tumor Progression and a Potential Therapeutic Target
5.
Coordinated Monitoring Pathways for Hematologic Disorders
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part VIII
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
4.
Should We Use DARA Up Front As First-Line Therapy in MM?
5.
From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation